Pronóstico del mercado europeo de terapias para enfermedades infecciosas hasta 2030 – Análisis regional – por clase de medicamento (antivirales, antibacterianos, antifúngicos y otros), indicación (VIH, hepatitis, tuberculosis, influenza, VPH y otros), vía de administración (Oral, Parenteral, Tópico y Otros) y Canal de Distribución (Farmacias Hospitalarias, Farmacias Minoristas y Otros)
El creciente enfoque en la financiación y la I+D en terapias para enfermedades infecciosas impulsa el mercado europeo de terapias para enfermedades infecciosas
La investigación y el desarrollo (I+D) es una parte fundamental del negocio de las empresas biofarmacéuticas y farmacéuticas. La I+D les permite lanzar nuevos productos para varias aplicaciones terapéuticas con un importante potencial médico y comercial. Además, los principales actores del mercado están invirtiendo en I+D para desarrollar tecnologías mejoradas y obtener una mayor participación en los ingresos.
Para crear soluciones a los problemas de salud más importantes que enfrentan actualmente Europa y el resto del mundo, la Unión Europea está invirtiendo en investigación, tecnología e innovación. La Comisión Europea ha liderado el camino en la promoción de la investigación, en particular la relacionada con la inmunidad y el manejo de enfermedades infecciosas. Entre 2007 y 2019, se asignaron más de 4,3 mil millones de dólares (4 mil millones) al estudio de las enfermedades infecciosas. Además, Horizonte Europa, la próxima iniciativa de financiación de la UE (2021-2027) para la investigación y la innovación (I+i), seguirá apoyando la I+i para enfermedades infecciosas, en particular las asociadas con la pobreza, las desatendidas y las que (re- )emergente.
Horizonte Europa es un programa dedicado a apoyar la investigación y la innovación. Para salvar barreras entre regiones y establecer colaboraciones tangibles, el programa pone un fuerte énfasis en garantizar la cooperación entre universidades, comunidades científicas, la industria, especialmente las pequeñas y medianas empresas, y los individuos. El Programa de Trabajo en Salud describe opciones de financiación en el marco de Horizonte Europa para la investigación relacionada con enfermedades infecciosas y la preparación y respuesta a pandemias. Por lo tanto, el creciente enfoque en I+D y la financiación de terapias para enfermedades infecciosas impulsan el crecimiento del mercado de terapias para enfermedades infecciosas.
Descripción general del mercado europeo de terapias para enfermedades infecciosas
El mercado europeo de terapias para enfermedades infecciosas está segmentado en Alemania, el Reino Unido, Francia, Italia, España y el resto de Europa. Europa ocupa una posición significativa en el mercado mundial de terapias para enfermedades infecciosas y se estima que registrará una CAGR notable durante 2022-2030. La región tiene una mayor incidencia de enfermedades virales crónicas y una gran demanda de desarrollo de nuevos medicamentos antivirales. Con 15.790 millones de dólares financiados entre 2007 y 2019 a través del Séptimo Programa Marco y Horizonte 2020 y los 1.100 millones de dólares prometidos para la investigación de la COVID-19, Europa desempeña un papel crucial en la financiación y coordinación de la investigación sobre enfermedades infecciosas. Según el Instituto Robert Koch, en Alemania, entre 400.000 y 600.000 pacientes sufren una infección nosocomial cada año, de los cuales entre 10.000 y 15.000 mueren. Los problemas típicos para los proveedores de atención médica son infecciones del sitio quirúrgico, infecciones del tracto urinario y neumonía. La demanda de agentes antiinfecciosos en Alemania está creciendo significativamente, lo que se atribuye al aumento de la población geriátrica, la creciente prevalencia de enfermedades virales crónicas y la creciente demanda de producir nuevas moléculas para que las áreas terapéuticas virales cumplan con las condiciones no satisfechas. Alemania es uno de los países líderes en fabricación de agentes antivirales y potencial de crecimiento en Europa debido a la alta calidad de sus productos terminados. Por ejemplo, Atriva Therapeutics GmbH, una empresa biofarmacéutica, desarrolló ATR-002 para tratar a pacientes con COVID-19 en un estudio de fase II para bloquear la propagación viral del SARS-CoV-2. Por lo tanto, debido a los factores antes mencionados, se espera que el mercado crezca significativamente en el país.
Ingresos del mercado europeo de terapias para enfermedades infecciosas y pronóstico hasta 2030 (millones de dólares estadounidenses)
Segmentación del mercado europeo de terapias para enfermedades infecciosas
El mercado europeo de terapias para enfermedades infecciosas se clasifica en clases de medicamentos , indicación, vía de administración, canal de distribución y país.
Según la clase de fármaco, el mercado europeo de terapias para enfermedades infecciosas se segmenta en antivirales, antibacterianos, antifúngicos y otros. El segmento antiviral tuvo la mayor cuota de mercado en 2022.
En términos de indicación, el mercado europeo de terapias para enfermedades infecciosas está segmentado en VIH, hepatitis, tuberculosis, influenza, VPH y otros. El VIH tuvo la mayor cuota de mercado en 2022.
Según la vía de administración, el mercado europeo de terapias para enfermedades infecciosas se segmenta en oral, parenteral, tópico y otros. El segmento oral tuvo la mayor cuota de mercado en 2022.
En términos de canal de distribución, el mercado europeo de terapias para enfermedades infecciosas está segmentado en farmacias hospitalarias, farmacias minoristas y otros. Las farmacias hospitalarias tuvieron la mayor cuota de mercado en 2022.
Por país, el mercado europeo de terapias para enfermedades infecciosas está segmentado en Alemania, el Reino Unido, Francia, Italia, España y el resto de Europa. Alemania dominó la cuota de mercado europeo de terapias para enfermedades infecciosas en 2022.
AbbVie Inc, Astellas Pharma Inc, Bayer AG, BioCryst Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc, Merck & Co Inc, Pfizer Inc y Shionogi & Co Ltd son algunas de las empresas líderes que operan en el mercado europeo de terapias para enfermedades infecciosas.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Infectious Disease Therapeutics Market - Key Market Dynamics
4.1 Europe Infectious Disease Therapeutics Market - Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Prevalence of Infectious Disease
4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
4.3 Market Restraints
4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
4.4 Market Opportunities
4.4.1 Escalating Threat of Antibiotic Resistance
4.5 Future Trends
4.5.1 Rising Number of Product Approvals and Launches
4.6 Impact of Drivers and Restraints:
5. Infectious Disease Therapeutics Market - Europe Analysis
5.1 Europe Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
6. Europe Infectious Disease Therapeutics Market Analysis - by Drug Class
6.1 Overview
6.2 Anti-Viral
6.2.1 Overview
6.2.2 Anti-viral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Anti-bacterial
6.3.1 Overview
6.3.2 Anti-bacterial: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Anti-fungal
6.4.1 Overview
6.4.2 Anti-fungal: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Others
6.5.1 Overview
6.5.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7. Europe Infectious Disease Therapeutics Market Analysis - by Indication
7.1 Overview
7.2 HIV
7.2.1 Overview
7.2.2 HIV: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Hepatitis
7.3.1 Overview
7.3.2 Hepatitis: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Tuberculosis
7.4.1 Overview
7.4.2 Tuberculosis: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Influenza
7.5.1 Overview
7.5.2 Influenza: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.6 HPV
7.6.1 Overview
7.6.2 HPV: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8. Europe Infectious Disease Therapeutics Market Analysis - by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Topical
8.4.1 Overview
8.4.2 Topical: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9. Europe Infectious Disease Therapeutics Market Analysis - by Distribution Channel
9.1 Overview
9.2 Hospital Pharmacies
9.2.1 Overview
9.2.2 Hospital Pharmacies: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Retail Pharmacies
9.3.1 Overview
9.3.2 Retail Pharmacies: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10. Europe Infectious Disease Therapeutics Market - Country Analysis
10.1 Europe Infectious Disease Therapeutics Market
10.1.1 Europe Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.1 Europe Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.2 Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Overview
10.1.1.3 Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 Germany: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.3.2 Germany: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.3.3 Germany: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.3.4 Germany: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.4 United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.1 Overview
10.1.1.5 United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.1 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.5.2 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.5.3 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.5.4 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.6 France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.1 Overview
10.1.1.7 France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.7.1 France: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.7.2 France: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.7.3 France: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.7.4 France: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.8 Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.8.1 Overview
10.1.1.9 Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.9.1 Italy: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.9.2 Italy: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.9.3 Italy: Infectious Disease Therapeutics Market Breakdown, by Route Of Administration
10.1.1.9.4 Italy: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.10 Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.10.1 Overview
10.1.1.11 Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.11.1 Spain: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.11.2 Spain: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.11.3 Spain: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.11.4 Spain: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.12 Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.12.1 Overview
10.1.1.13 Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.13.1 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.13.2 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.13.3 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.13.4 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
11. Infectious Disease Therapeutics Market-Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Infectious Disease Therapeutics Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Pfizer Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Gilead Sciences Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 F. Hoffmann-La Roche Ltd
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Shionogi & Co Ltd
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Bayer AG
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 BioCryst Pharmaceuticals Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 GSK Plc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 AbbVie Inc
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Merck & Co Inc
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Astellas Pharma Inc
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
List of Tables
Table 1. Europe Infectious Disease Therapeutics Market Segmentation
Table 2. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Drug Class
Table 3. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication
Table 4. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 5. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 6. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Country
Table 7. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 8. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 9. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 10. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 11. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 12. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 13. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 14. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 15. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 16. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 17. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 18. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 19. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 20. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 21. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route Of Administration
Table 22. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 23. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 24. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 25. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 26. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 27. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 28. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 29. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 30. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 31. Recent Inorganic Growth Strategies in the Infectious Disease Therapeutics Market
Table 32. Recent Organic Growth Strategies in the Infectious Disease Therapeutics Market
List of Figures
Figure 1. Europe Infectious Disease Therapeutics Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. Europe Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
Figure 4. Europe Infectious Disease Therapeutics Market Share (%) - by Drug Class (2022 and 2030)
Figure 5. Anti-viral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 6. Anti-bacterial: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Anti-fungal: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Europe Infectious Disease Therapeutics Market Share (%) - by Indication (2022 and 2030)
Figure 10. HIV: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Tuberculosis: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Influenza: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. HPV: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Europe Infectious Disease Therapeutics Market Share (%) - by Route Of Administration (2022 and 2030)
Figure 17. Oral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Parenteral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Topical: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Europe Infectious Disease Therapeutics Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 22. Hospital Pharmacies: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Retail Pharmacies: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. Europe Infectious Disease Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 26. Europe Infectious Disease Therapeutics Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 27. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 28. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 29. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 30. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 31. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 32. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 33. Growth Strategies in the Infectious Disease Therapeutics Market
1. AbbVie Inc
2. Astellas Pharma Inc
3. Bayer AG
4. BioCryst Pharmaceuticals Inc
5. F. Hoffmann-La Roche Ltd
6. Gilead Sciences Inc
7. GSK Plc
8. Merck & Co Inc
9. Pfizer Inc
10. Shionogi & Co Ltd
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe infectious disease therapeutics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Europe infectious disease therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe infectious disease therapeutics market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.